Studies suggest a benefit of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk in carriers of a BRCA1/2 pathogenic/likely pathogenic (P/LP) variant, but the magnitude of the effect is not well-understood, and evidence is mixed regarding age at which RRSO should be undertaken and the specific P/LP variant (BRCA1 vs. BRCA2) carried. More data are needed regarding the efficacy of salpingectomy without oophorectomy in reducing the risk for ovarian cancer in carriers of a BRCA1/2 P/LP variant.